Twice-daily chemoradiotherapy must still be the choice for patients with limited-stage small-cell lung cancer

被引：0
作者：
Franco, Fernando [1 ]
Perez-Callejo, David [1 ]
Provencio, Mariano [1 ]
机构：
[1] Hosp Univ Puerta Hierro Majadahonda, Med Oncol Dept, Madrid, Spain
来源：
JOURNAL OF THORACIC DISEASE | 2017年 / 9卷 / 09期
关键词：
DAILY THORACIC RADIOTHERAPY; RANDOMIZED PHASE-III; CISPLATIN CHEMOTHERAPY; CHEST RADIOTHERAPY; RADIATION-THERAPY; ETOPOSIDE; TRIAL; METAANALYSIS; IRRADIATION; CISPLATIN/ETOPOSIDE;
D O I：
10.21037/jtd.2017.08.113
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：2843 / 2846
页数：4
相关论文
共 19 条
[1]   Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer [J].
De Ruysscher, D ;
Pijls-Johannesma, M ;
Bentzen, SM ;
Minken, A ;
Wanders, R ;
Lutgens, L ;
Hochstenbag, M ;
Boersma, L ;
Wouters, B ;
Lammering, G ;
Vansteenkiste, J ;
Lambin, P .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (07) :1057-1063
[2]   Chest radiotherapy in limited-stage small cell lung cancer: facts, questions, prospects [J].
De Ruysscher, D ;
Vansteenkiste, J .
RADIOTHERAPY AND ONCOLOGY, 2000, 55 (01) :1-9
[3]   Omission of elective node irradiation on basis of CT-scans in patients with limited disease small cell lung cancer: A phase II trial [J].
De Ruysscher, Dirk ;
Bremer, Robert-Harm ;
Koppe, Friederike ;
Wanders, Stofferinus ;
van Haren, Erik ;
Hochstenbag, Monique ;
Geeraedts, Wiel ;
Pitz, Cordula ;
Simons, Jean ;
ten Velde, Guul ;
Dohmen, Jo ;
Snoep, Gabriel ;
Boersma, Liesbeth ;
Verschueren, Tom ;
van Baardwijk, Angela ;
Dehing, Cary ;
Pijls, Madelon ;
Minken, Andre ;
Lambin, Philippe .
RADIOTHERAPY AND ONCOLOGY, 2006, 80 (03) :307-312
[4]   Phase II trial of cisplatin/etoposide and concurrent radiotherapy followed by paclitaxel/carboplatin consolidation for limited small-cell lung cancer: Southwest Oncology Group 9713 [J].
Edelman, MJ ;
Chansky, K ;
Gaspar, LE ;
Leigh, B ;
Weiss, GR ;
Taylor, SA ;
Crowley, J ;
Livingston, R ;
Gandara, DR .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) :127-132
[5]   Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: A Radiation Therapy Oncology Group 9609 phase II study [J].
Ettinger, DS ;
Berkey, BA ;
Abrams, RA ;
Fontanesi, J ;
Machtay, M ;
Duncan, PJ ;
Curran, WJ ;
Movsas, B ;
Byhardt, RW .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) :4991-4998
[6]   Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial [J].
Faivre-Finn, Corinne ;
Snee, Michael ;
Ashcroft, Linda ;
Appel, Wiebke ;
Barlesi, Fabrice ;
Bhatnagar, Adityanarayan ;
Bezjak, Andrea ;
Cardenal, Felipe ;
Fournel, Pierre ;
Harden, Susan ;
Le Pechoux, Cecile ;
McMenemin, Rhona ;
Mohammed, Nazia ;
O'Brien, Mary ;
Pantarotto, Jason ;
Surmont, Veerle ;
Van Meerbeeck, Jan P. ;
Woll, Penella J. ;
Lorigan, Paul ;
Blackhall, Fiona .
LANCET ONCOLOGY, 2017, 18 (08) :1116-1125
[7]   Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer [J].
Fried, DB ;
Morris, DE ;
Poole, C ;
Rosenman, JG ;
Halle, JS ;
Detterbeck, FC ;
Hensing, TA ;
Socinski, MA .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (23) :4837-4845
[8]   Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer [J].
Han, JY ;
Cho, KH ;
Lee, DH ;
Kim, HY ;
Kim, EA ;
Lee, SY ;
Lee, JS .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (15) :3488-3494
[9]   Etoposide, ifosfamide and cisplatin (VIP) plus concurrent radiation therapy for previously untreated limited small cell lung (SCM): a Hoosier Oncology Group (HOG) phase II cancer study [J].
Hanna, N ;
Ansari, R ;
Fisher, W ;
Shen, JZ ;
Jung, SH ;
Sandler, A .
LUNG CANCER, 2002, 35 (03) :293-297
[10]  
KOSMIDIS PA, 1994, SEMIN ONCOL, V21, P23
12